Summary of Business Results for the Third Quarter Ended September 30, 2024
[Japan GAAP](Consolidated)
November 8, 2024 | ||
Company | Medrx Co., Ltd. | Lidted on the TSE |
Stock Code | 4586 | URL : https://www.medrx.co.jp |
Representative | Yonehiro Matsumura, President & CEO | |
Contact | Takeshi Fujioka, Management Department Director | TEL +81-03-3664-9665 |
Expected starting date of dividend payment : －
Preparation of supplementary financial document : None
Results briefing : None
(Rounded down to million yen)
1. Consolidated business results for the nine months ended September 2024 (January 1, 2024 through September 30, 2024)
(1) Consolidated results of operations | (% change from the previous corresponding period) | |||||||
Net sales | Operating income | Ordinary income | Profit attributable to | |||||
owners of parent | ||||||||
Million | ||||||||
yen | % | Million yen | % | Million yen | % | Million yen | % | |
Nine months ended Sep. 2024 | 255 | 771.3 | -379 | - | -343 | - | -320 | - |
Nine months ended Sep. 2023 | 29 | 208.8 | -670 | - | -668 | - | -671 | - |
(Note) Comprehensive income: | ||||||||
Nine months ended September 2024 : -340 million yen (-%) | ||||||||
Nine months ended September 2023 : -670 million yen (-%) | ||||||||
Net income | Diluted net | |||||||
Per share | Income per shar | |||||||
Yen | Yen | |||||||
Nine months ended Sep. 2024 | -7.60 | - | ||||||
Nine months ended Sep. 2023 | -20.00 | - | ||||||
(Note) Diluted net income per share is not applicable due to net loss share | ||||||||
(2) Consolidated financial position | ||||||||
Total assets | Net assets | Shareholders' equity | ||||||
ratio | ||||||||
Million yen | Million yen | % | ||||||
As of Sep. 2024 | 2,712 | 2,623 | 94.8 | |||||
As of Dec.2023 | 2,052 | 1,924 | 90.6 | |||||
(Reference) Shareholders' equity : | ||||||||
As of September 2024 : 2,570 million yen | ||||||||
As of December 2023 : 1,858 million yen | ||||||||
2. Dividends | ||||||||
Annual dividend | ||||||||
End of 1Q | End of 2Q | End of 3Q | Year-end | Total | ||||
Yen | Yen | Yen | Yen | Yen | ||||
Year ended Dec. 2023 | - | 0.00 | - | 0.00 | 0.00 | |||
Year ended Dec. 2024 | - | 0.00 | - | |||||
Year ended Dec. 2024 (forecast) | - | - | 0.00 | 0.00 |
3. Forecast of consolidated business results for the fiscal year ending December 2024 (January 1, 2024 through December 31, 2024)
(% change from the previous year) | |||||||||
Net sales | Operating income | Ordinary income | Net income | Net income | |||||
Per share | |||||||||
Million | Million | Million | Million | ||||||
yen | % | yen | % | yen | % | yen | % | Yen | |
Year ending Dec. 2024 | 259 | 877.4 | -919 | - | -868 | - | -846 | - | -17.87 |
(Note) Revisions to business forecast for the current quarter: None
―1―
- Notes
(1) | Changes in significant subsidiaries during the period : | Yes |
Newly included : 1 company (Company name) MedRX Australia Pty Ltd | ||
(2) | Application of accounting procedures specific to preparation of the consolidated quarterly | None |
financial statements : |
- Change in accounting policies, accounting estimates and restatement
① | Changes in accounting policies associated with revision of accounting standards: | None |
② | Changes in accounting policies other than ①: | None |
③ | Changes in accounting estimates: | None |
④ | Restatement: | None |
- Shares outstanding (common stock)
① Number of share outstanding at the end of period (treasury stock included) :
As of Septenber 2024 | 47,345,100 shares |
As of December 2023 | 38,365,100 shares |
- Treasury stock at the end of period :
As of September 2024 | 2 shares |
As of December 2023 | 2 shares |
- Average number of stock during period :
Nine months ended September 2024 | 42,150,340 shares |
Nine months ended September 2023 | 33,568,629 shares |
- Financial results reports are exempt from audit conducted by certified public accountants or an audit firm.
- Explanation regarding appropriate use of business forecasts and other special instructions
Forecasts regarding future performance in this material are based on information currently available to the company and certain assumptions that the company deems to be reasonable at the time this report was prepared. The company does not make promises about the achievements. Actual results may differ significantly from the forecasts due to various factors.
―2―